NOT YET ON TRACK: RETROSPECTIVE CHART ANALYSIS REVEALS PHYSICIAN'S TREATMENT APPOACHES IN SLE FALL SHORT OF NEW EULAR GUIDANCE (EULAR 2024) - Mar 29, 2024 - Abstract #POS1181; Pres time: Jun 14, 2024; 12:00 PM - 01:30 PM; Location: Poster View; "2 Notably, since the previous guidelines update in 2019, anifrolumab received approval for treatment of SLE, and belimumab and voclosporin for lupus nephritis (LN)... The first EULAR recommendation states that hydroxychloroquine (HCQ) should be used in all SLE patients, unless contraindicated...Third, EULAR guidelines recommend rheumatologists should consider adding traditional DMARDs (methotrexate, azathioprine, or mycophenolate mofetil) and/or biologics to patients who fail to respond to HCQ or those who fail to taper to maintenance GC doses of ≤ 5mg... While SLE management practices in the US and EU5 share similarities, there are notable differences, particularly in HCQ and GC use. Importantly, both regions show increasing adoption of biologics, especially for steroid-dependent patients, partially bridging the gap in adherence to the new EULAR recommendations. Future research is needed to understand the drivers of these geographical differences and how..."
Retrospective data • Glomerulonephritis • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Rheumatoid Arthritis • Systemic Lupus Erythematosus
|
|
S. May1; V. Strand2; R. Rex1; M. Yarnall1
|